Screener
Protagonist Therapeutics PTGX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's restricted cash?
- Protagonist Therapeutics (PTGX) reported restricted cash of $287K in Q2 2026.
- How has Protagonist Therapeutics's restricted cash changed year-over-year?
- Protagonist Therapeutics's restricted cash decreased by 1.0% year-over-year, from $290K to $287K.
- What is the long-term trend for Protagonist Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's restricted cash has grown at a 95.7% compound annual growth rate (CAGR), from $10K to $287K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Protagonist Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude